Nahdi Medical CoSAU:4164 -0.80%61 EBITDA Margin % is 17.02% as of Mar. 2026, which is 8% below its 10-year median of 18.40. GuruFocus rates SAU:4164 with a GF Score™ of 61/100 and a GF Value™ of ﷼140.28 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 665 Healthcare Providers & Services companies, Nahdi Medical Co ranks better than 66.17% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nahdi Medical Co's EBITDA for the
three
months ended in Mar. 2026 was ﷼476 Mil. Nahdi Medical Co's Revenue for the
three
months ended in Mar. 2026 was ﷼2,794 Mil. Therefore, Nahdi Medical Co's EBITDA margin for the quarter that ended in Mar. 2026 was 17.02%.
Nahdi Medical Co (SAU:4164) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Nahdi Medical Co EBITDA Margin % Related Terms
Nahdi Medical Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Nahdi Medical Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nahdi Medical Co EBITDA Margin % Competitor Comparison
For the Pharmaceutical Retailers subindustry, Nahdi Medical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nahdi Medical Co EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Nahdi Medical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Nahdi Medical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nahdi Medical Co (SAU:4164) has a EBITDA Margin % of 17.02% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nahdi Medical Co and its competitors. This is near median its historical median of 18.40. Over the past decade, Nahdi Medical Co's EBITDA Margin % has ranged from 16.63 to 18.69. According to the industry distribution chart, Nahdi Medical Co ranks #225 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 33.8%.
Is Nahdi Medical Co's EBITDA Margin % too high?
Nahdi Medical Co's current EBITDA Margin % of 17.02% is near median its 10-year median of 18.40. Over the past 10 years, this metric has ranged from a low of 16.63 to a high of 18.69. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. Nahdi Medical Co's value of 17.02% is 66.2% above this industry median. Based on the distribution chart, Nahdi Medical Co ranks #225 out of 665 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Nahdi Medical Co has a GF Score™ of 61/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nahdi Medical Co's EBITDA Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Nahdi Medical Co ranks #225 out of 665 companies for EBITDA Margin %. This puts Nahdi Medical Co in the upper half of its industry. The industry median EBITDA Margin % is 10.24. Nahdi Medical Co's value of 17.02% is 66.2% above this benchmark. Historically, Nahdi Medical Co's own EBITDA Margin % has ranged from 16.63 to 18.69 over the past decade. While the company's 10-year median is 18.40 vs. the industry median of 10.24, Nahdi Medical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nahdi Medical Co's current EBITDA Margin % of 17.02% is 66.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nahdi Medical Co and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nahdi Medical Co's current EBITDA Margin % is 17.02%, which is near median its own 10-year median of 18.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nahdi Medical Co stock overvalued right now?
Based on GuruFocus' analysis, Nahdi Medical Co (SAU:4164) is currently considered Significantly Undervalued. The stock's GF Value™ is ﷼140.28, compared to a current price of ﷼93.25 — trading 33.5% below its estimated fair value. The current EBITDA Margin % is 17.02%, which is near median its 10-year median of 18.40 and 66.2% above the Healthcare Providers & Services industry median of 10.24. Nahdi Medical Co's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nahdi Medical Co (SAU:4164), the current EBITDA Margin % is 17.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nahdi Medical Co (SAU:4164) Overvalued in 2026?
Based on GuruFocus' analysis, Nahdi Medical Co stock appears to be undervalued.
The current stock price of ﷼93.25 is trading 33.5% below its estimated GF Value™ of ﷼140.28.
GuruFocus considers Nahdi Medical Co to be Significantly Undervalued.
Key valuation signals for SAU:4164:
EBITDA Margin %: 17.02% (near median its 10-year median of 18.40)
GF Value™: ﷼140.28 vs. price of ﷼93.25 (33.5% below fair value)
Industry Position: 66.2% above the Healthcare Providers & Services median (#225 of 665)
No single metric tells the full story. See the SAU:4164 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nahdi Medical Co is engaged in the wholesale and retail trading of cosmetics, pharmaceutical products, special and healthy foods, and medical equipment. It has two operating segments: Front Shop and Pharma.
61GF Score
Get the complete analysis for SAU:4164
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:4164 has been successfully added to your 
